PARIS, FRANCE, December 1, 2025 – Qynapse is present at CTAD Clinical Trials on Alzheimer’s Disease 2025 in San Diego.
Meet Olivier Courrèges and Michael Tunkelrott and discover how Qynapse’s clinically validated AI solutions are advancing Alzheimer’s disease research, clinical trials, and precision imaging.
This year’s CTAD showcases excellent presentations with a major emphasis on imaging biomarkers, ARIA monitoring, and reliable quantitative MRI and PET measures for evaluating therapeutic response. These are precisely the areas where QyScore® and QyPredict® deliver best-in-class, regulatory-cleared analytics:
– FDA-cleared & CE-marked volumetric MRI quantification
– Automated lesion detection
– Harmonised, trial-ready PET quantification (Amyloid-PET, Tau-PET, FDG-PET)
– Predictive AI models supporting screening, enrichment, and clinical progression forecasting
Trusted by leading Alzheimer’s centers, CROs, and biopharmaceutical partners globally, Qynapse integrates seamlessly into clinical and research workflows—delivering secure, validated, quantitative insights built for Phase 2–3 AD trials, early detection programs, and routine clinical care.
Let’s shape the future of precision neuroimaging together.